Synergistic Combination of ALK4:ActRIIB Heteromultimer with Emerging Technologies for Enhanced SMA Treatment

This inventive concept integrates the patented recombinant ALK4:ActRIIB heteromultimer with distinct emerging technologies, including AI, IoT, blockchain, and novel biomaterials, to create a more effective and personalized system for treating spinal muscular atrophy (SMA).

The original patent addressed the treatment of SMA using recombinant ALK4:ActRIIB heteromultimer. However, there remains a need to improve treatment efficacy, monitoring, and personalization. This inventive concept tackles these limitations by combining the heteromultimer with cutting-edge technologies to provide a more comprehensive and efficient SMA treatment system.

The inventive concept consists of four synergistic combinations: (1) a machine learning-based predictive model integrated with the recombinant ALK4:ActRIIB heteromultimer for optimizing treatment efficacy, (2) a wearable IoT device connected to a blockchain-based data storage system for monitoring treatment outcomes, (3) a novel biomaterial for sustained release of the heteromultimer, and (4) an AI-powered genomics analysis platform for personalized treatment. These combinations enable real-time monitoring, data-driven decision-making, and targeted therapy, ultimately leading to improved patient outcomes.

The novelty of this inventive concept lies in the unexpected integration of the patented recombinant ALK4:ActRIIB heteromultimer with emerging technologies, resulting in a more effective, personalized, and efficient SMA treatment system. The inventive step is the recognition of the synergistic potential of combining these distinct technologies to address the limitations of the original patent.

Alternative embodiments may include the use of different machine learning algorithms, varying IoT device configurations, or alternative biomaterials for sustained release. Variations may also involve integrating the heteromultimer with other emerging technologies, such as augmented reality or 5G networks, to further enhance SMA treatment.

This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of rare disease treatment and personalized medicine. The target market includes pharmaceutical companies, biotech firms, and healthcare providers seeking to improve SMA treatment outcomes and patient quality of life.